TVL Journal Entry

Special Report: XORTX Therapeutics Inc. (NASDAQ: XRTX / TSXV: XRTX)

We are pleased to bring investors a new, special report by The Venture Letter™ venture stock newsletter on XORTX Therapeutics Inc. (NASDAQ & TSXV: XRTX) at the following link TVL – Special Report – XORTX Therapeutics Inc. – 0224.

We are excited by the prospects for XORTX and the company’s efforts to provide new and much-needed orphan drug therapy to slow progressive kidney disease. We invite investors to read our special report and take a close look at XORTX Therapeutics, now approaching its third and most important FDA drug trial.

Biotech stocks are in a bull market right now and we see XRTX as a perfect company to investigate.

Good luck and good hunting.

 

#theventureletter #stocksinfocus #XORTX #biotech #biotechs #biotechstocks #XBI #nasdaqlisted #stocks #

 

Related Posts

Gain insight into venture stocks & venture stock markets that only career professionals and seasoned veterans can provide.

Learn from some of the best who have learned what positives and challenges publicly-traded, venture companies can experience.

Sign up now for FREE with The Venture Letter!

"*" indicates required fields

facebooktwitterlinkedin

Home | Journal | Special Reports | About | Contact | Subscribe for Free | Privacy Policy | Terms of Services | Disclaimer

©2016 - The Venture Letter™

The Venture Letter™ does not provide investment advice and the information provided by The Venture Letter™ should not be considered a recommendation to buy or sell any security. The Venture Letter™ does not endorse or recommend the business, products, services or securities of any company mentioned by The Venture Letter™.

Back To Top